Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular ...

Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and ...

The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on February 20, 2026, and its existing cash and ...

As of Wednesday, February 25, United Therapeutics Corporation’s UTHR share price has surged by 10.84%, which has investors questioning if this is right time to sell.

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating ...

Training harder may do more than build muscle—it could transform your gut. Researchers found that intense workouts change the ...

A growing body of preclinical research is converging on a provocative idea: that the mental health benefits of physical exercise might one day be delivered in pill form. Scientists have identified ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.

Japan’s Chugai Pharmaceutical (TYO: 4519) and Swiss ADC specialist Araris Biotech have announced that the Tokyo firm has exercised its option under the research collaboration and option to license ...

KOSDAQ-listed LigaChem Biosciences is currently conducting clinical trials for LCB84, an antibody-drug conjugate (ADC) candidate. This was transferred to Janssen Biotech, a subsidiary of Johnson & ...